Cargando…

Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib

Autophagy is a critical survival pathway for cancer cells under conditions of stress. Thus, induction of autophagy has emerged as a drug resistance mechanism. This study is to determine whether autophagy is activated by a novel multikinase inhibitor linifanib, thereby impairing the sensitivity of he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Hongming, Wang, Zhanggui, Jiang, Liming, Sui, Xinbing, You, Liangkun, Shou, Jiawei, Jing, Zhao, Xie, Jiansheng, Ge, Weiting, Cai, Xiujun, Huang, Wendong, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202209/ https://www.ncbi.nlm.nih.gov/pubmed/25327881 http://dx.doi.org/10.1038/srep06683

Ejemplares similares

Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2020)

The role of STAT3 in autophagy
por: You, Liangkun, et al.
Publicado: (2015)

Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines
por: You, Liangkun, et al.
Publicado: (2015)

Autophagy: A novel therapeutic target for hepatocarcinoma (Review)
por: WANG, ZHANGGUI, et al.
Publicado: (2014)

Linifanib
Publicado: (2012)

Analysis of potential genes and pathways associated with the colorectal normal mucosa–adenoma–carcinoma sequence
por: Wu, Zhuoxuan, et al.
Publicado: (2018)

p53-induced autophagy and senescence
por: Sui, Xinbing, et al.
Publicado: (2015)

Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review)
por: SUI, XINBING, et al.
Publicado: (2013)

Repositioning linifanib as a potent anti-necroptosis agent for sepsis
por: Yu, Liang, et al.
Publicado: (2023)

Nec-1 Enhances Shikonin-Induced Apoptosis in Leukemia Cells by Inhibition of RIP-1 and ERK1/2
por: Han, Weidong, et al.
Publicado: (2012)

Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2(+)/calcineurin/Erk pathway
por: Liu, Zhen, et al.
Publicado: (2019)

Autophagy-associated immune responses and cancer immunotherapy
por: Pan, Hongming, et al.
Publicado: (2016)

Salvianolic acid B, a novel autophagy inducer, exerts antitumor activity as a single agent in colorectal cancer cells
por: Jing, Zhao, et al.
Publicado: (2016)

OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers
por: Monroig-Bosque, Paloma del C., et al.
Publicado: (2018)

E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2022)

miR-26a enhances autophagy to protect against ethanol-induced acute liver injury
por: Han, Weidong, et al.
Publicado: (2015)

Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS
por: Iqbal, Muzaffar, et al.
Publicado: (2014)

Quantitation of cell-free DNA in blood is a potential screening and diagnostic maker of breast cancer: a meta-analysis
por: Wang, Huadi, et al.
Publicado: (2017)

The Multikinase Inhibitor AD80 Induces Mitotic Catastrophe and Autophagy in Pancreatic Cancer Cells
por: Lima, Keli, et al.
Publicado: (2023)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

Spectrophotometric and molecular modelling studies on in vitro interaction of tyrosine kinase inhibitor linifanib with bovine serum albumin
por: Wani, Tanveer A., et al.
Publicado: (2017)

Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer
por: Chen, Jing, et al.
Publicado: (2016)

Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma
por: Han, Xinghua, et al.
Publicado: (2017)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study
por: You, Liangkun, et al.
Publicado: (2022)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

The role of autophagy in colitis-associated colorectal cancer
por: Wu, Yuhui, et al.
Publicado: (2018)

miR-26a attenuates colitis and colitis-associated cancer by targeting the multiple intestinal inflammatory pathways
por: Zhang, Wei, et al.
Publicado: (2021)

Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China
por: Zhai, Chongya, et al.
Publicado: (2018)

Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
por: Oranratnachai, Songporn, et al.
Publicado: (2022)

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
por: Jiang, Hao, et al.
Publicado: (2023)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Inositol polyphosphate multikinase signaling in the regulation of metabolism
por: Lee, Joo-Young, et al.
Publicado: (2012)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

CircUBAP2-mediated competing endogenous RNA network modulates tumorigenesis in pancreatic adenocarcinoma
por: Zhao, Rongjie, et al.
Publicado: (2019)

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
por: Asahina, Hajime, et al.
Publicado: (2012)

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
por: Horger, Marius, et al.
Publicado: (2009)

Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach
por: Alqahtani, Saleh A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v74tmp7ium3iatplqcsvpun6ud